SU
SUN.LSE Surgical Innovations Group plc
- Market cap
- GBX 3.03M
- P/E
- -
- P/B
- 0.44x
- ROE
- -13.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is SUN.LSE undervalued?
Graham numberThe Graham number of Surgical Innovations Group plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Surgical Innovations Group plc fundamental analysis
No fundamental analysis for Surgical Innovations Group plc yet.
Surgical Innovations Group plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Surgical Innovations Group plc
Surgical Innovations Group plc, together with its subsidiaries, engages in the design, manufacture, and export of medical products for use in laparoscopic and robotic minimally invasive surgery in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. It operates through SI Brand, Original Equipment Manufacturer (OEM), and Distribution segments. The company provides YelloPort Elite port access systems; YelloPort + Resposable port access systems…
Full company profileSurgical Innovations Group plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Surgical Innovations Group plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.09M | 8.75M | 11.0M | 10.7M | 6.33M | 9.13M | 11.3M | 12.0M | 11.9M | 11.6M | 24.1M |
| Gross Profit | 2.06M | 3.72M | 4.67M | 4.33M | 1.27M | 3.13M | 3.92M | 3.45M | 3.44M | 3.05M | 6.99M |
| Operating Income | 469K | 581K | 620K | -2.43M | -3.79M | -480K | 41.0K | -596K | -791K | -731K | -920K |
| EBITDA | 1.41M | 1.99M | 2.24M | 1.08M | -884K | 247K | 628K | 161K | -99.0K | -73.0K | 132K |
| Net Income | 716K | 626K | 725K | -2.62M | -3.28M | -456K | 264K | -509K | -1.94M | -895K | -992K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 6.83M | 18.5M | 18.8M | 16.3M | 16.3M | 15.7M | 15.6M | 14.3M | 12.2M | 11.6M | 10.9M |
| Total Liabilities | 996K | 4.82M | 4.41M | 4.12M | 5.25M | 5.05M | 4.63M | 3.84M | 3.70M | 4.00M | 3.47M |
| Shareholders' Equity | 5.84M | 13.7M | 14.4M | 12.2M | 11.1M | 10.7M | 11.0M | 10.5M | 8.54M | 7.65M | 7.40M |
| Cash & Short-term Investments | 775K | 1.71M | 2.49M | 1.28M | 5.28M | 3.64M | 2.20M | 1.21M | 195K | 813K | 361K |
| Total Debt | 53.0K | 2.44M | 2.11M | 2.09M | 3.27M | 2.79M | 2.16M | 1.66M | 1.24M | 665K | 587K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.85M | 1.61M | 1.65M | 594K | 1.04M | -433K | 486K | 400K | -74.0K | 569K | 800K |
| Capital Expenditure | 601K | 775K | 486K | 516K | 155K | 657K | 1.08M | 688K | 335K | 61.0K | 16.0K |
| Free Cash Flow | 2.24M | 833K | 1.16M | 78.0K | 887K | -1.09M | -592K | -288K | -409K | 508K | 784K |
| Ratios | |||||||||||
| ROE | 12.3% | 4.6% | 5.0% | -21.5% | -29.5% | -4.3% | 2.4% | -4.9% | -22.7% | -11.7% | -13.4% |
| ROA | 10.5% | 3.4% | 3.9% | -16.1% | -20.0% | -2.9% | 1.7% | -3.6% | -15.9% | -7.7% | -9.1% |
| Net Profit Margin | 11.8% | 7.2% | 6.6% | -24.4% | -51.8% | -5.0% | 2.3% | -4.2% | -16.3% | -7.7% | -4.1% |
| Debt to Equity | 0.01x | 0.18x | 0.15x | 0.17x | 0.29x | 0.26x | 0.20x | 0.16x | 0.15x | 0.09x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Surgical Innovations Group plc dividends
Surgical Innovations Group plc has not paid dividends in the last 9 fiscal years.
Last stock split: 67637:35071 on Dec 6, 1996.
Who owns Surgical Innovations Group plc
- Insiders 53.64%
- Institutions 20.80%
- Public & others 25.56%
- Shares outstanding 933M
- Free float 343M
Surgical Innovations Group plc company profile
- Company name
- Surgical Innovations Group plc
- Ticker
- SUN.LSE
- ISIN
- GB0004016704
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 93
- Fiscal year end
- December
- Address
- Clayton Wood House, Leeds, United Kingdom, LS16 6QZ
- Phone
- 44 11 3230 7597
- Website
- sigroupplc.com
About Surgical Innovations Group plc
Surgical Innovations Group plc, together with its subsidiaries, engages in the design, manufacture, and export of medical products for use in laparoscopic and robotic minimally invasive surgery in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. It operates through SI Brand, Original Equipment Manufacturer (OEM), and Distribution segments. The company provides YelloPort Elite port access systems; YelloPort + Resposable port access systems; LogiCut, a disposable laparoscopic scissors; Logic, a reusable laparoscopic grasping forceps and dissectors; LogiFlex, a dual purpose, Resposable device for blunt dissection and gastric band retrieval; FastClamp, a reusable laparoscopic clamping system, designed to fixate a range of instrumentation in position during minimally invasive surgery; PretzelFlex, a pretzel shaped organ and tissue retractor, designed for use in minimally invasive surgery; and LogiTube, a calibration tubing for gastric pouch sizing during sleeve gastrectomy, mini gastric bypass/one-anastomosis gastric bypass, or revision surgery for these procedures. It also researches, develops, manufactures, and distributes minimally invasive devices for third party medical device companies through either own label or co-branding; and minimally invasive technology products for precision engineering applications. In addition, the company distributes specialist medical products; and designs and manufactures autologous blood products. It sells its products through independent healthcare distributors, as well as its own label products through OEM relationships. Surgical Innovations Group plc was incorporated in 1988 and is headquartered in Leeds, the United Kingdom.
Surgical Innovations Group plc management
5- Mr. Alex WarnockChief Executive Officer · born 1965
- Mr. David Mark AndersonCFO, Director & Secretary · born 1963
- Mr. Richard WalleyOperations Director
- Mr. Stephen SeedChief Compliance Officer
- Mr. Damian DonnellyChief Commercial Officer